Optigenex Inc. Announces Rollout of Activar(R) AC-11(R) Oral Supplements and Activar(R) AC-11(R) Next Generation Skin

NEW YORK, NY, Jul 28 (MARKET WIRE) --
Optigenex Inc. (PINKSHEETS: OPGX) announced today its partner Ekson Farma
is prepared to launch its family of AC-11(R) oral supplements and skin
care products under the brand name Activar(R) for distribution throughout
the major pharmacies in Turkey. Under an exclusive license signed in
early 2008, Ekson has invested significant capital, resources and time in
determining market acceptance of Optigenex's patented technology and has
also devoted considerable efforts towards clinical and scientific
research to broaden the market applications for its unique anti-aging
products. The agreement and subsequent commercialization by Ekson sets
the stage for the introduction of AC-11(R) to educated and
health-conscious Turkish consumers and represents another important
strategic initiative in the company's plans to establish AC-11(R) as a
recognized international brand.

All-natural, and standardized at a minimum of 8 per cent Carboxy Alkyl
Esters ("CAEs(TM)"), AC-11(R) is the only patented aqueous extract of the
Uncaria species that can make the following therapeutic claims ("DNA
repair, Immune enhancement and Inhibition of pro-inflammatory agents")
which are validated by a broad spectrum of scientific and clinical
studies.

AC-11(R) already has gained a major foothold in Japan and has been
introduced in other select territories of Asia as a branded ingredient
used by over 100 manufacturers and distributors in a variety of anti-aging
cosmetic, cosmeceutical and dietary supplement products. With their
regional alliance together, Optigenex and Middle Eastern based Ekson Farma
anticipate similar market penetration, growth and expansion for AC-11(R)

Daniel Zwiren, president and CEO of Optigenex Inc., said, "We are
delighted to have a company with the scientific pedigree and reputation
of Ekson Farma as part of our growing list of marketing and distribution
partners. Moreover, we believe the unique scientific properties of
AC-11(R) along with Ekson's research will allow us to grow our business
rapidly in this key geographic region."

Doctor Yaman Er, president of Ekson Farma, added, "We are very pleased
with the reception AC-11(R) has received and attribute this attention to
the key differentiators of AC-11(R) supported by clinical and scientific
studies. Those studies validate the efficacy of this all-natural
ingredient, which is harvested in the Amazon Rainforest and manufactured
by Centroflora Group Botucatu, Brazil. Consumer demand in our market is
driven by new and result-oriented technologies. We believe our alliance
with Optigenex provides us with the opportunity to introduce Turkey and
the Middle East to the next major brand in oral and topical applications."

About Ekson Farma:

Ekson Farma: Founded in 1994, Ekson Farma is an applied sciences and
marketing company focused on providing wellness solutions and related
technologies to physicians, pharmacies and the general medical community.
Ekson's strategy is to select superior and innovative products validated
by clinical and scientific studies, establish consumer and physician
acceptance through test marketing and ultimately distribute those products
with the goal of improving the quality of life for health conscious
consumers and patients. Ekson through its collaboration with research
partner OKSANTE LABORATORIES is noted for its development of diagnostic
tools utilizing DNA sequencing and molecular diagnostics with an emphasis
on early detection of disease and DNA mutations.

About Optigenex Inc.:

Optigenex Inc. is a formulator, distributor and provider of proprietary
next generation skin care, supplements and bulk ingredient featuring
AC-11(R) (Formerly known as C-MED-100(R)) a patented compound, as it core
product. AC-11(R) is a bioactive, water-soluble form of the medicinal herb
Uncaria tomentosa. For more information about Optigenex please email or
call the company at: dzwiren@optigenex.com 201 355 2098.

* The statements made in this press release have not been evaluated by the
Food and Drug Administration. The products mentioned in this release are
not intended to diagnose, treat, cure or prevent any disease.

Contact:
Optigenex
dzwiren@optigenex.com
201 355 2098

Copyright 2009, Market Wire, All rights reserved.

-0-